- Home
- IMA vs VGI Comparison
IMA vs VGI Comparison
Compare IMA & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$6.49
Company Overview
Basic Information| Metric | IMA | VGI |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.2M | 90.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMA | VGI |
|---|---|---|
| Price | $6.49 | $7.85 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 50.1K | 46.0K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.19 | $6.68 |
| 52 Week High | $18.00 | $7.99 |
Technical Indicators
Market Signals| Indicator | IMA | VGI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.15 |
| Support Level | N/A | $7.77 |
| Resistance Level | N/A | $7.86 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 79.22 |
Price Performance
Historical Comparison IMA
VGI
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.